The Latest Cardiac and Vascular News
ABBOTT PARK, Ill., Dec. 15, 2017 /PRNewswire/ — The board of directors of Abbott (NYSE: ABT) today increased the company’s quarterly common dividend to 28 cents per share from 26.5 cents per share. This marks the 376th consecutive quarterly dividend to be paid by Abbott since 1924. The cash […]
ABBOTT PARK, Ill., Nov. 6, 2017 /PRNewswire/ — Abbott (NYSE: ABT) today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the company’s MitraClip device for treatment of people with mitral regurgitation (MR), a serious, progressive heart disease in which the mitral […]
DENVER, Oct. 30, 2017 /PRNewswire/ — Abbott (NYSE: ABT) today announced that patients who underwent minimally-invasive implantation with a XIENCE coronary stent for left-main coronary artery disease had the same long-lasting health outcomes at three years but felt better more quickly than […]
ABBOTT PARK, Ill., Oct. 23, 2017 /PRNewswire/ — Abbott (NYSE: ABT) has secured U.S. Food and Drug Administration (FDA) clearance for the Confirm Rx™ Insertable Cardiac Monitor (ICM), the world’s first and only smartphone compatible ICM designed to help physicians remotely identify cardiac arrhythmias. With […]
ABBOTT PARK, Ill., Sept. 22, 2017 /PRNewswire/ — Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for one of Abbott’s most widely-used implantable cardioverter defibrillators (ICD) and associated high voltage leads. The approval of […]
Time to throw in the towel for Abbott on this generation of their Absorb BVS because of slow sales. However, there could still be a platform for this technology… Abbott halts global sales of 1st-gen Absorb stents SEPTEMBER 8, 2017 BY FINK […]
ABBOTT PARK, Ill., Aug. 29, 2017 – Today, Abbott notified physicians of updates to its implantable pacemakers and defibrillators as part of its ongoing commitment to continuously improve patient care. The new device updates include a Battery Performance Alert for […]
ABBOTT PARK, Ill., Aug. 28, 2017 /PRNewswire/ — Abbott (NYSE: ABT) announced today it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left Ventricular Assist System (also known as an LVAD). The HeartMate 3 system provides a new […]
ABBOTT PARK, Ill., June 9, 2017 /PRNewswire/ — The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 26.5 cents per share. This marks the 374th consecutive quarterly dividend to be paid by Abbott since […]
ABBOTT PARK, Ill., May 8, 2017 /PRNewswire/ — Abbott (NYSE: ABT) today announced CE Mark and first use of the new Confirm Rx Insertable Cardiac Monitor (ICM), the world’s first smartphone compatible ICM that will help physicians identify difficult to detect […]
